The effect of Milurit on secondary hyperuricaemia following cytostatic treatment in haemoblastosis patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008875:Middle Aged; D011087:Polycythemia Vera / Q000188:drug therapy*; D011247:Pregnancy; D014527:Uric Acid / Q000097:blood*
D000970:Antineoplastic Agents; D014527:Uric Acid; D000493:Allopurinol